According to an update released by analysts at Stifel Nicolaus the broker has now set a ‘Hold’ rating on shares of Vernalis PLC (LON:VER) with a price target of 24.
Stifel Nicolaus on Friday reiterated Vernalis PLC’s analyst rating as ‘Hold’ with its price target of 24 highlighting a potential increase of 9.31% from Vernalis PLC’s current price of 21.96.
Over the last twelve months Vernalis PLC’s stock price has decreased from 50.63 to 21.96, a change of -56.64%.
Vernalis PLC has 526,351,000 shares in issue which have a share price of 21.96 giving Vernalis PLC a market capitalisation of 115.56M GBp.
The company has a 50 day moving average of 24.55 and a 200 day moving average of 31.87. The 52 week high shares of Vernalis PLC have reached is 51.95 whilst the 52 week low for the company’s shares is 20.
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.